

West London Mental Health NHS Trust Performance in Initiating Q2 18/19

| Id | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | First Participant Recruited? | Date of First Participant Recruited | Duration between Date Site Selected and Date Site Confirmed | Duration between Date Site Confirmed and First Participant Recruited | Duration between Date Site Selected and First Participant Recruited | Date Site Invited | Date Site Selected | HRA Approval Date | Date Site Confirmed By Sponsor | Date Site Confirmed | Non-Confirmation Status | Date Site Ready To Start | Reasons for Delay | Comments | Reasons for delay correspond to: |
|--------|--|---|---|------------------------------|-------------------------------------|---|--|---|-------------------|--------------------|-------------------|--------------------------------|---------------------|-------------------------|--------------------------|---|---|----------------------------------|
| 127499 | 17/EE/0114 | 221275 | A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study) | Yes | 01/01/2018 | 34 | -9 | 25 | 07/12/2017 | 07/12/2017 | 12/06/2017 | 09/01/2018 | 10/01/2018 | Please Select... | 10/01/2018 | | The first participant was recruited prior to site selection due to study design (feeder study) and contract delays. | Please Select... |
| 127500 | 16/SS/0115 | 206867 | A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD). | Yes | 11/12/2017 | 20 | 26 | 46 | 20/10/2017 | 26/10/2017 | 25/08/2016 | 10/11/2017 | 15/11/2017 | Please Select... | 15/11/2017 | | | Please Select... |
| 127501 | 17/SC/0081 | 221195 | A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease | Yes | 16/11/2017 | 0 | 22 | 22 | 23/10/2017 | 25/10/2017 | 21/04/2017 | 25/10/2017 | 25/10/2017 | Please Select... | 25/10/2017 | | | Please Select... |
| 127502 | 17/SC/0595 | 233484 | A Double-blind, Placebo-controlled, Relapse | No | | | | | 05/02/2018 | 12/03/2018 | 12/02/2018 | | | Please Select... | | A - Permissions delayed/denied H - Contracting | Pharmacy support issues | NHS Provider |

West London Mental Health NHS Trust Performance in Delivery Q2 18/19

| Id | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure Of Trial | Comments |
|-------|--|---|---|-----------------------------------|---|---|---|--|--|---|--|-----------------------------|--|
| 32649 | 16/WS/0138 | 208282 | A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (ACADIA) | Number Agreed | 5 | 5 | Date Agreed | 02/04/2018 | 2 | 04/10/2017 | 2 | Withdrawn By Sponsor | |
| 32650 | 17/SC/0081 | 221195 | "A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease" | Number Agreed | 2 | 2 | Date Agreed | 01/02/2020 | 2 | 28/11/2017 | 2 | Withdrawn By Sponsor | The Sponsor decided to stop recruitment early, because there was a potential overlap with another study of theirs. |
| 32651 | 16/SS/0115 | 206867 | A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD). | Number Agreed | 3 | 3 | Date Agreed | 31/12/2018 | 1 | 16/02/2018 | 1 | Withdrawn By Sponsor | Following a futility analysis the data monitoring committee (Sponsor) decided to close the study early. |
| 32814 | 16/NE/0399 | 215044 | A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB) | Number Agreed | 4 | 4 | Date Agreed | 03/02/2018 | 3 | 09/01/2018 | 3 | Withdrawn By Sponsor | Early termination due to lack of efficacy. |
| 32815 | 13/SC/0332 | 164229 | DEME 4149 A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833 | Not Available / Not Agreed | | | Not Available / Not Agreed | | | 26/03/2018 | 1 | Withdrawn By Sponsor | Early termination due to lack of efficacy. |

| | | | | | | | | | | | | | |
|-------|------------|--------|--------------------|---------------|---|---|-------------|------------|---|------------|----|----------------------|--|
| 32824 | 14/LO/1994 | 161812 | DEME 3882 AMARANTH | Number Agreed | 7 | 7 | Date Agreed | 01/10/2016 | 5 | 12/06/2018 | 13 | Recruitment Finished | |
|-------|------------|--------|--------------------|---------------|---|---|-------------|------------|---|------------|----|----------------------|--|